| Stepwise activation of p63 and the MEK/ERK pathway induces the expression of ARL4C to promote oral squamous cell carcinoma cell proliferation. | Stepwise activation of p63 and the MEK/ERK pathway induces the expression of ARL4C to promote oral squamous cell carcinoma cell proliferation.
Alkhatib DZR, Thi Kim Truong T, Fujii S, Hasegawa K, Nagano R, Tajiri Y, Kiyoshima T. | 10/28/2023 |
| ARL4C is associated with epithelial-to-mesenchymal transition in colorectal cancer. | ARL4C is associated with epithelial-to-mesenchymal transition in colorectal cancer.
Kanai R, Uehara T, Yoshizawa T, Kamakura M, Nakajima T, Kinugawa Y, Iwaya M, Asaka S, Kitazawa M, Nagaya T, Ota H., Free PMC Article | 06/2/2023 |
| ARL4C depletion suppresses the resistance of ovarian cancer to carboplatin by disrupting cholesterol transport and autophagy via notch-RBP-Jkappa-H3K4Me3-OSBPL5. | ARL4C depletion suppresses the resistance of ovarian cancer to carboplatin by disrupting cholesterol transport and autophagy via notch-RBP-Jκ-H3K4Me3-OSBPL5.
Yang J, Peng S, Zhang K. | 11/29/2022 |
| Identification of Neural Progenitor Cell-associated Chemoradiotherapy Resistance Gene Set (ARL4C, MSN, TNFAIP6) for Prognosis of Glioma. | Identification of Neural Progenitor Cell-associated Chemoradiotherapy Resistance Gene Set (ARL4C, MSN, TNFAIP6) for Prognosis of Glioma.
Yang Y, Xu X, Xie Y, Liu Y, Ning C, Ai Y, Lv C, Wei H, Ge X, Yi T, Piao Y, Wang X, Jin X. | 10/1/2022 |
| RAF1-MEK/ERK pathway-dependent ARL4C expression promotes ameloblastoma cell proliferation and osteoclast formation. | RAF1-MEK/ERK pathway-dependent ARL4C expression promotes ameloblastoma cell proliferation and osteoclast formation.
Fujii S, Ishibashi T, Kokura M, Fujimoto T, Matsumoto S, Shidara S, Kurppa KJ, Pape J, Caton J, Morgan PR, Heikinheimo K, Kikuchi A, Jimi E, Kiyoshima T. | 01/8/2022 |
| ARL4C might serve as a prognostic factor and a novel therapeutic target for gastric cancer: bioinformatics analyses and biological experiments. | ARL4C might serve as a prognostic factor and a novel therapeutic target for gastric cancer: bioinformatics analyses and biological experiments.
Xie N, Bai Y, Qiao L, Bai Y, Wu J, Li Y, Jiang M, Xu B, Ni Z, Yuan T, Shi Y, Wu K, Xu F, Wang J, Dong L, Liu N., Free PMC Article | 09/25/2021 |
| High ARL4C expression is associated with Peritoneal Dissemination in Gastric Cancer. | ASO Author Reflections: ARL4C and Peritoneal Dissemination in Gastric Cancer.
Hu Q, Mimori K. | 05/16/2020 |
| ARL4C is involved in the initiation of the premalignant stage. | ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target.
Kimura K, Matsumoto S, Harada T, Morii E, Nagatomo I, Shintani Y, Kikuchi A., Free PMC Article | 03/21/2020 |
| ARL4C antisense oligonucleotides (ASO) accumulated in cancer cells more efficiently than the surrounding normal cells in the liver and decreased ARL4C expression in the tumor. These results suggest that ARL4C ASO represents a novel targeted nucleic acid medicine for the treatment of primary and metastatic liver cancers. | Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth.
Harada T, Matsumoto S, Hirota S, Kimura H, Fujii S, Kasahara Y, Gon H, Yoshida T, Itoh T, Haraguchi N, Mizushima T, Noda T, Eguchi H, Nojima S, Morii E, Fukumoto T, Obika S, Kikuchi A. | 03/14/2020 |
| ARL4C stabilized by AKT/mTOR pathway promotes the invasiveness of PTEN-deficient glioblastoma cells. | ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma.
Chen Q, Weng HY, Tang XP, Lin Y, Yuan Y, Li Q, Tang Z, Wu HB, Yang S, Li Y, Zhao XL, Fu WJ, Niu Q, Feng H, Zhang X, Wang Y, Bian XW, Yao XH. | 12/21/2019 |
| High ADP-ribosylation factor-like protein 4C (ARL4C) expression in endometriosis-associated ovarian cancer is a significantly independent predictive factor for worse 5-year overall survival and 5-year progression-free survival. | ADP-ribosylation factor-like 4C predicts worse prognosis in endometriosis-associated ovarian cancers.
Wakinoue S, Chano T, Amano T, Isono T, Kimura F, Kushima R, Murakami T. | 07/27/2019 |
| High ARL4C expression was associated with the depth of invasion and Peritoneal Dissemination in Gastric Cancer. | Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer.
Hu Q, Masuda T, Sato K, Tobo T, Nambara S, Kidogami S, Hayashi N, Kuroda Y, Ito S, Eguchi H, Saeki H, Oki E, Maehara Y, Mimori K. | 03/16/2019 |
| We demonstrate that ARL4C knockdown likely attenuates osteogenesis of hASCs through inhibition of the Wnt signaling pathway. These results provide new insights into the mechanisms of osteogenic differentiation and provide a potential molecular target for bone tissue engineering. | Knockdown of ARL4C inhibits osteogenic differentiation of human adipose-derived stem cells through disruption of the Wnt signaling pathway.
Wang W, Wang S, Liu X, Gu R, Zhu Y, Zhang P, Liu Y, Zhou Y. | 03/17/2018 |
| ARL4C is expressed due to hypomethylation in the 3'-UTR for certain types of cancers and that ARL4C methylation status is involved in squamous cell carcinoma cell function. | Epigenetic upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes tumorigenesis of lung squamous cell carcinoma.
Fujii S, Shinjo K, Matsumoto S, Harada T, Nojima S, Sato S, Usami Y, Toyosawa S, Morii E, Kondo Y, Kikuchi A., Free PMC Article | 02/24/2018 |
| Arl4c as a novel Wnt signal target molecule that links epithelial tubulogenesis to tumourigenesis. | Arl4c is a key regulator of tubulogenesis and tumourigenesis as a target gene of Wnt-β-catenin and growth factor-Ras signalling.
Matsumoto S, Fujii S, Kikuchi A. | 02/4/2017 |
| Results indicated that overexpression of Arl4c might contribute to the tumorigenesis and might play a pivotal role in the progression of CRC. | Clinical and prognostic significance of Arl4c expression in colorectal cancer.
Chen X, Su Z, Wang S, Xu H. | 12/17/2016 |
| Arl4c is involved in tumorigenesis and might represent a novel therapeutic target for suppressing proliferation and invasion of colorectal and lung cancer cells. | Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target.
Fujii S, Matsumoto S, Nojima S, Morii E, Kikuchi A. | 12/12/2015 |
| an important role of LXRs in the coordinated regulation of lipid metabolic and inflammatory gene programs in macrophages | Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target.
Hong C, Walczak R, Dhamko H, Bradley MN, Marathe C, Boyadjian R, Salazar JV, Tontonoz P., Free PMC Article | 05/28/2011 |
| ARL7 might modulate the intracellular vesicular transport via interaction with microtubules. | ADP-ribosylation factor like 7 (ARL7) interacts with alpha-tubulin and modulates intracellular vesicular transport.
Wei SM, Xie CG, Abe Y, Cai JT. | 01/21/2010 |
| Study shows that three related Arf-like GTPases Arl4a, Arl4c, and Arl4d, are able to recruit ARNO and other cytohesins to the plasma membrane by binding to their PH domains irrespective of whether they are in the diglycine or triglycine form. | The Arl4 family of small G proteins can recruit the cytohesin Arf6 exchange factors to the plasma membrane.
Hofmann I, Thompson A, Sanderson CM, Munro S. | 01/21/2010 |